← All Seres Therapeutics, INC filings

Seres Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
MCRB
Seres Therapeutics, INC
10-K: Seres Therapeutics Shifts Focus to I&I Amidst Going Concern Doubts
Seres Therapeutics, Inc. reports a strategic pivot towards inflammatory and immune diseases, pausing further investment in its lead infectious disease candidate SER-155's Phase 2 study due to funding needs, while detailing 2025 financial results including a net income from continuing operations.
NASDAQ
MCRB
Seres Therapeutics, INC
10-K: Seres Therapeutics Navigates Post-VOWST Sale, Focuses on SER-155 Development
Seres Therapeutics details its financial position and strategic shift following the sale of its VOWST business, emphasizing the development of SER-155 and other live biotherapeutic candidates.
NASDAQ
MCRB
Seres Therapeutics, INC
10-K: Seres Therapeutics Outlines Capital Stock Structure and Reports 2023 Financial Results
Seres Therapeutics details its capital stock, reports a net loss of $113.7 million for 2023, and outlines strategic restructuring efforts.